https://orcid.org/0000-0001-9466-2125
References
- Ohta A, Nagai M, Nishina M, et al. Prevalence and incidence of polymyositis and dermatomyositis in Japan. Mod Rheumatol. 2014;24(3):477–480.
- Mandel DE, Malemud CJ, Askari AD. Idiopathic inflammatory myopathies: a review of the classification and impact of pathogenesis. Int J Mol Sci. 2017;18(1084)
- van der Kooi AJ, de Visser M. Idiopathic inflammatory myopathies. Handb Clin Neurol. 2014;119:495–512.
- Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol. 2017;52(1):20–33.
- Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol. 2015;42(2):282–291.
- Tsukamoto H. Dermatomyositis/polymyositis. J Jpn Soc Intern Med. 2015;104(10):2125–2131.
- Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013;88(1):83–105.
- Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor l family proteins. Arthritis Rheum. 2012;64(2):513–522.
- Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–407.
- Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–347.
- Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100.
- András C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438–444.
- Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–532.
- Lu X, Yang H, Shu X, et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS One. 2014;9(4):e94128.
- Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatol (Oxford). 2007;46(1):25–28.
- Masiak A, Kulczycka J, Czuszyńska Z, et al. Clinical characteristics of patients with anti-TIF1-γ antibodies. Reumatologia. 2016;54(1):14–18.
- Meisterfeld S, Röber N, Conrad K, et al. A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1-γ. Br J Dermatol. 2017;177(2):590–593.
- Oldroyd A, Sergeant JC, New P, et al.; UKMyoNet. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis. Rheumatology. 2019;58(4):650–655.
- Hemminki K, Sundquist K, Sundquist J, et al. Risk of cancer of unknown primary after hospitalization for autoimmune diseases. Int J Cancer. 2015;137(12):2885–2895.
- Selva-O'Callaghan A, Grau JM, Gámez-Cenzano C, et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med. 2010;123(6):558–562.
- Mahmood S, de Llano Rodríguez SM. 18F-FDG PET detection of unknown primary malignancy in dermatomyositis. Clin Nucl Med. 2012;37(8):e204–e205.
- Ohashi M, Shu E, Tokuzumi M, et al Anti-p155/140 antibody-positive dermatomyositis with metastasis originating from an unknown site. Acta Derm Venereol. 2011;91(1):84–85.